Every intervention Outliyr has scored for mood, ranked by its BioHarmony score for this use case rather than its overall rating. The number beside each name is how well that one thing works for mood; the tier beside it is what it is worth once safety, cost and effort are counted across everything else.
66 of 118 evaluated interventions score 3.0+ out of 10 for mood · 23 comparisons
For mood, Saffron earns 7.8/10 because the evidence points to a plausible use case without proving a universal response. Mahmoudi et al. 2026 is the best anchor here because it reports 34…
Read the Saffron report →Magnesium mood earns 7.6/10 because Tarleton 2017 anchors the most relevant signal. Magnesium fits mood when low intake, stress load, mineral loss, or a form-specific target makes deficiency correction plausible. The score…
Read the Magnesium report →Mood is a 7.5/10 fit for HRV Biofeedback, based on the evidence summarized in Goessl, Curtiss, Hofmann 2017. Medium pooled effects in meta-analyses; anger and irritability show largest gains. Vann-Adibe 2025 remote…
Read the HRV Biofeedback report →On mood, Infrared Sauna deserves 7.3/10 because Kihara 2002 makes the claim plausible but incomplete. The existing rationale points to this narrower claim: Post-session mood improvement is one of the most reliable…
Read the Infrared Sauna report →Mood reaches 7.0/10 because Ji 2024 found photobiomodulation improved depression symptoms with an SMD of -0.55 across 11 trials. That is a real clinical signal, though protocols and populations vary. Red Light…
Read the Red Light Therapy report →A 6.8/10 mood rating fits Neurofeedback, since Adler et al. 2024 points to a real but bounded effect. Mood benefits likely come from improved self-awareness, arousal control, and sleep regulation. The PTSD…
Read the Neurofeedback report →Glycine mood earns 6.5/10 because Soh 2024 anchors the most relevant signal. Glycine fits mood because glycine participates in sleep signaling, glutathione, collagen, methylation, and nervous-system balance, depending on the endpoint. The…
Read the Glycine report →Evidence puts Vagus Nerve Stimulation at 6.5/10 for mood, mainly through Jost et al. 2026. Implanted VNS is FDA-approved for treatment-resistant depression, while Conway 2025 found mixed primary and secondary antidepressant results…
Read the Vagus Nerve Stimulation report →For users targeting mood, TRT (Testosterone Replacement Therapy) earns 6.5/10 because Snyder 2016 reports T Trials main paper, n=790; sexual-function benefit, some mood/depressive-symptom benefit, no primary vitality or walking-distance benefit. Zarrouf 2009…
Read the TRT (Testosterone Replacement Therapy) report →The evidence shows a modest acute mood lift from hard aerobic intervals, with a meta-analysis reporting a small effect size (dabout 0.3) in healthy adults Poon 2024. Norwegian 4x4 training targets mood…
Read the Norwegian 4×4 report →A 6.0/10 for mood fits Zone 2 Cardio because Lang 2024 supports direction more than certainty. The existing rationale points to this narrower claim: Moderate aerobic exercise improves depressive symptoms in many…
Read the Zone 2 Cardio report →Mood scores 6.0/10 on the bipolar-depression adjunct literature, which is positive but unsettled. Berk 2008 (n=75) found a meaningful MADRS advantage (mean difference -8.05, 95% CI -13.16 to -2.95), and a meta-analysis…
Read the NAC (N-Acetylcysteine) report →Vitamin D3 + K2 mood earns 6.0/10 because Jolliffe 2021 anchors the most relevant signal. Vitamin D3 + K2 fits mood when deficiency, bone risk, immune seasonality, or fat-soluble nutrient gaps are…
Read the Vitamin D3 + K2 report →Lion's Mane mood earns 6.0/10 because Nagano 2010 anchors the most relevant signal. Lion's Mane fits mood when the goal is gentle mushroom-based support for cognition, mood, nerve biology, or gut-immune signaling…
Read the Lion’s Mane report →For mood, Tongkat Ali lands at 6.0/10 because Talbott 2013 supports the strongest part of the claim. The existing rationale points to this narrower claim: the cited study reported Profile of Mood…
Read the Tongkat Ali report →The main limitation behind Ashwagandha's 6.0/10 mood score is that the evidence points to a plausible use case without proving a universal response. Alsanie et al. 2026 is the best anchor here…
Read the Ashwagandha report →Mood is a 5.8/10 use case for PEMF (Pulsed Electromagnetic Field Therapy), not a blanket claim. The intended Martiny 2010 depression paper supports a transcranial low-voltage PEMF signal in treatment-resistant depression, but…
Read the PEMF (Pulsed Electromagnetic Field Therapy) report →For users targeting mood, Creatine Monohydrate earns 5.6/10 because Toniolo 2017 reports Augmentation; 67% vs 18% remission at 6 g/day. The score stays conditional because Creatine Monohydrate still needs better outcome data…
Read the Creatine Monohydrate report →For users targeting mood, Molecular Hydrogen earns 5.5/10 because Dhillon 2024 reports 25-article systematic review; mixed preliminary clinical evidence, heterogeneity, and need for stronger trials. Zhou 2024 points in the same direction,…
Read the Molecular Hydrogen report →The 5.5/10 mood score reflects evidence plus practical constraints. Mood support is indirect through stress reduction and stimulant smoothing. Moshfeghinia 2024 supports psychiatric-symptom improvement across limited mental-disorder trials, while monotherapy mood evidence…
Read the L-Theanine report →Mood scores 5.5/10. Users widely report a reliable post-sauna mood lift, and the systematic review by Hussain 2018 found self-reported wellbeing benefits across pooled studies. The proposed pathways include endorphin and beta-endorphin…
Read the Traditional Sauna (Finnish Dry-Heat) report →Phosphatidylserine scores 5.5/10 for mood, with the best signal coming from Duan et al. 2025. Mood signal is strongest in older adults and stressed users, with small elderly data from Maggioni 1990…
Read the Phosphatidylserine report →Mood receives a modest 5.5/10 rating for Whole-Body Vibration because direct depression or anxiety trials are thin. Any mood effect likely comes through pain relief, movement confidence, circulation, and exercise-like stimulation rather…
Read the Whole-Body Vibration report →Mood support is moderate and indirect. Voznesenskaia 2010 reported quality-of-life improvements rather than formal mood-scale deltas in the n=728 cohort. The strongest depression-relevant data is animal-only: Tallerova 2011 outperformed imipramine on TNF-alpha…
Read the Bromantane (Ladasten) report →Selank earns 5.5/10 for mood because Zozulia 2008 reports Corrected key human anxiety comparator study; 62 patients, Selank versus medazepam; old v0.x anxiety identifier was unrelated. Medvedev 2014 points in the same…
Read the Selank report →Current evidence gives Earthing a modest 5.5/10 rating for mood, based on the short-term improvement reported in a small double-blind pilot Chevalier 2015. Earthing for the mood use case rests on a…
Read the Earthing report →Population fit explains the 5.5/10 mood score for Omega-3 because the evidence points to a plausible use case without proving a universal response. Appleton et al. 2021 is the best anchor here…
Read the Omega-3 report →Cold plunge for mood lift has the most consistent acute signal in the literature. Cain 2025 PLOS ONE meta-analysis (n=3,177 across 11 studies) found significant stress reduction at 12 hours post-exposure. Yankouskaya…
Read the Cold Plunge report →The practical mood read on Methylene Blue is 5.5/10 because Rothenberg 2025 anchors the strongest signal. The existing rationale points to this narrower claim: Mood evidence remains historical and mixed. Older psychiatric…
Read the Methylene Blue report →Mood earns 5.5/10 because Semaglutide can improve metabolic health and body confidence in some users, while appetite and reward dampening can flatten mood in others. Wilding 2021 supports weight loss, but weight…
Read the Semaglutide report →The mood case for Modafinil lands at 5.5/10 because the evidence points to a plausible use case without proving a universal response. Jung H et al. 2026 is the best anchor here…
Read the Modafinil report →The mood case for Time-Restricted Eating lands at 5.4/10 because the evidence points to a plausible use case without proving a universal response. Chen X et al. 2026 is the best anchor…
Read the Time-Restricted Eating report →The use-case score for Tirzepatide and mood is 5.2/10, reflecting the paucity of dedicated mood trials and only anecdotal signals from real-world reports Franco 2025. Tirzepatide has been studied extensively for weight…
Read the Tirzepatide report →The practical mood read on Taurine is 5.0/10 because Zhang 2007 reports Mechanistic in vivo anxiety model supporting glycine receptor pathway. The score stays conditional because Taurine still needs better outcome data…
Read the Taurine report →Rapamycin mood earns 5.0/10 because Harrison 2009 anchors the most relevant signal. Rapamycin fits mood when mTORC1 modulation, autophagy, immune aging, or senescence biology is the actual target. The score stays bounded…
Read the Rapamycin report →For mood, Ketogenic Diet earns 5.0/10 because the evidence points to a plausible use case without proving a universal response. Leung GKW et al. 2025 is the best anchor here because it…
Read the Ketogenic Diet report →Sabroxy scores 5.0/10 for mood because mood effects are plausible through arousal or monoamine pathways but remain lightly replicated. The strongest support comes from Dinda B. et al. 2015, but the practical…
Read the Sabroxy (Oroxylum indicum Extract) report →Ca-AKG (Calcium Alpha-Ketoglutarate) earns 5.0/10 for mood because Shahmirzadi 2020 is the cleanest verified anchor for this report. The existing rationale points to this narrower claim: No mood signal in the literature…
Read the Ca-AKG (Calcium Alpha-Ketoglutarate) report →Mood earns a conditional 5.0/10. The Sarris 2009 KADSS trial enrolled people across an anxiety-depression spectrum and reported improvements in both anxiety and depressive symptoms, but the antidepressant signal is weaker and…
Read the Kava (Piper methysticum) report →For mood, Celebrex (Celecoxib) earns 5.0/10 because the evidence points to a plausible use case without proving a universal response. Zeng X et al. 2026 is the best anchor here because it…
Read the Celebrex (Celecoxib) report →Mood relevance is weak because tryptophan is counterbalanced by other LNAAs competing at transporters. No direct mood trial was verified.
Read the Essential Amino Acids report →Mood may improve when glycemic volatility improves in type 2 diabetes, but metformin has no direct mood indication. B12 depletion can work in the opposite direction if unmonitored.
Read the Metformin report →Mood improvements appear as secondary outcomes in post-COVID, fibromyalgia, TBI, and PTSD-adjacent literature. Zilberman-Itskovich 2022 reports secondary mood gains within a sham-controlled long-COVID trial. Mood is not a primary established indication for…
Read the Hyperbaric Oxygen Therapy report →Mood benefit is indirect via oxidative-inflammatory burden and fatigue reduction. No strong direct depression or anxiety RCT base.
Read the Astaxanthin report →Mood benefit is inferred from resistance-training effects, effortful movement, and self-efficacy. WB-EMS-specific mood RCTs are thin, so this remains indirect despite plausible exercise-mediated endorphin and confidence effects.
Read the Full-Body EMS report →Mood scores 4.5 on the well-established effect of moderate outdoor aerobic activity on affect, which rucking delivers, though the benefit is shared with walking and not specific to the added load.
Read the Rucking (Weighted Walking) report →Acute hard exercise can lift mood, but maximal sprints are uncomfortable enough that the post-session lift is inconsistent. Most evidence is indirect through fitness rather than direct mood trials.
Read the Sprinting (Sprint Interval Training) report →Overlaps with the depression signal but broader mood claims in healthy users are not supported. Community reports here are inconsistent.
Read the Curcumin report →Armstrong 2012 supports mood impairment from mild dehydration in healthy young women; correction is likely fastest when symptoms are dehydration-linked.
Read the Electrolytes report →Mood scores 4.0/10. Fatigue, irritability, and low mood are documented symptoms of vitamin C deficiency that improve with repletion, and the brain's high vitamin C concentration supports a plausible role in neurotransmitter…
Read the Vitamin C (Ascorbic Acid) report →Mood is 4.0/10. Polyphenol-rich diets associate with lower depression risk in cohorts, but this is confounded by overall diet quality and lacks direct class-level RCT support.
Read the Polyphenols (Dietary) report →Dopaminergic and serotonergic system interactions in animal models. Human mood evidence is not established, so this remains an exploratory neurochemical score rather than a depression or anxiety treatment claim.
Read the BPC-157 report →Plausible mood benefit via 5-HT1A activity and anxiety reduction, but no robust human depression or mood RCTs; the signal is indirect.
Read the Full-Spectrum Hemp (CBD) report →Acute alertness and mood elevation reported anecdotally; chronic use associated with anxiety, irritability, panic, and insomnia per Shekelle 2003 which showed 2.2-3.6x increased odds of psychiatric, autonomic, and GI symptoms. Not a…
Read the Ephedrine report →Any mood lift is best interpreted as an exercise effect; direct BFR-specific mood trials are not established.
Read the Blood-Flow Restriction Training report →Mood keeps a 3.5 because GHK-Cu has indirect anti-inflammatory and neuroprotective signals, but no direct antidepressant or mood RCT. Pickart 2012 supports a cognitive-health mechanism review, not mood efficacy.
Read the GHK-Cu report →Mood-lift reports exist, and BDNF mechanisms are relevant to mood biology, but Semax has no controlled human mood trial and should not be positioned as an antidepressant.
Read the Semax report →Double-edged. Mild anxiolysis could support mood at low doses, but the community mood-blunting signal at 100+ mg or chronic daily use is a meaningful tradeoff. Amsterdam 2012 found exploratory antidepressant activity in…
Read the Apigenin report →NAC has independent psychiatric data and glycine affects NMDA signaling, but the GlyNAC combination has no direct mood trial, so the case is indirect. Scores 3.5/10.
Read the GlyNAC (Glycine + N-Acetylcysteine) report →No direct mood, depression, or anxiety trials. Any benefit would be indirect through inflammation and is unproven.
Read the Ergothioneine report →Traditional adaptogenic use and community reports suggest better well-being in some users, but no RCT has tested mood endpoints directly.
Read the Shilajit report →Immune-mood links are real in general medicine, but thymosin alpha-1 has no direct depression, anxiety, or mood RCT. Use this as exploratory only.
Read the Thymosin Alpha-1 report →No direct mood or depression RCT base; mechanistic links through inflammation are speculative for this compound.
Read the Spirulina report →Body-image and quality-of-life improvements appear in HIV lipodystrophy evidence, but tesamorelin is not a mood treatment. Mood benefit is most likely secondary to body composition, sleep, or metabolic improvements.
Read the Tesamorelin report →No direct mood RCT base for exogenous ketones. Any benefit is indirect via energy or focus.
Read the Exogenous Ketones report →Indirect via fatigue and stress pathways; no direct depression or anxiety RCT base for any of the three mushrooms.
Read the Adaptogenic Mushrooms (Reishi, Cordyceps, Chaga) report →Nothing matches those filters.
Head-to-head reports and category rankings that name a winner on this use case.
Bromantane and semax tie at 7.1, and they are the only two in this category scored strong recommend. Selank is third at 6.9 if anxiety rather than focus…
Shilajit at 7.4, phosphatidylserine at 7.3, tongkat ali at 7.0. TRT ranks seventh at 5.7 and wins nine of the eleven use cases outright. That inversion is the…
Melatonin, dosed low. It scores 8.2 against apigenin's 6.7 and wins the sleep rows outright. The morning hangover apigenin markets against comes from taking too much, not from…
Both score anxiety 7.5, so the tie-breaker is time. L-theanine works in about an hour and you take it when you need it. Ashwagandha takes eight weeks and…
Bromantane, for anything you plan to repeat. It scores 7.1 against phenylpiracetam's 5.5 and wins every shared use case that is not a floor tie: energy 6.2 to…
Neither, yet. Both have zero human trials, zero human pharmacokinetics and research-only access. PE-22-28 scores 4.9 and dihexa 4.4, and the gap is entirely safety: dihexa potentiates the…
Epitalon, if sleep is the question. It scores sleep quality 6.5 against pinealon's 1.7, because it acts on the pineal gland and melatonin output while pinealon is a…
Magnesium glycinate is magnesium bound to glycine, so if you take it you already take both. That kills the question for sleep. The real decision: magnesium scores higher…
The scores tie at 6.3 and 6.4 and every shared subrating sits within half a point, so the numbers decide nothing. Access and evidence decide it. Gonadorelin is…
Kisspeptin-10 scores 6.4 and TRT 5.7, and TRT still wins 13 of the 15 use cases both reports score. The higher number reflects dependency and reversibility, not effect.…
Lion's Mane scores 7.2 and the reishi, cordyceps and chaga blend category scores 5.8. If cognition is the goal, buy the one species: lion's mane takes cognition-focus 7.0…
Red light therapy scores 8.0 and PEMF 7.5, so the panel is the better first buy for most people. PEMF wins on bone and joint pain, where a…
Saffron, at 7.8 out of 10 for mood. For mood, Saffron earns 7.8/10 because the evidence points to a plausible use case without proving a universal response.
Of the top-scoring options, Glycine is the least expensive at about $2 a month, scoring 6.5 out of 10 for mood.
66 of the 118 interventions evaluated for mood score 3.0 out of 10 or better, which is the cut-off for appearing on this page.
